Amphotericin B

Cerebral Cryptococcosis, Histoplasmosis, Coccidioidomycosis + 25 more

Treatment

28 FDA approvals

20 Active Studies for Amphotericin B

What is Amphotericin B

Amphotericin B

The Generic name of this drug

Treatment Summary

Amphotericin B is a medication used to treat fungal infections. It is especially effective against Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, and Cryptococcus neoformans, with concentrations ranging from 0.03 to 1.0 mcg/mL in vitro. Candida albicans is generally very susceptible to amphotericin B, but other species may be less so. Pseudallescheria boydii and Fusarium sp. are often resistant to the antibiotic. It has no effect on bacteria, viruses, or rickettsiae.

Fungizone

is the brand name

Amphotericin B Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Fungizone

Amphotericin B

1966

10

Approved as Treatment by the FDA

Amphotericin B, otherwise called Fungizone, is approved by the FDA for 28 uses like severe Fungal infection caused by Basidiobolus spp. and severe Fungal infection caused by Conidiobolus spp. .

severe Fungal infection caused by Basidiobolus spp.

severe Fungal infection caused by Conidiobolus spp.

severe Mucocutaneous leishmaniasis

severe Fungal infection caused by sporotrichosis spp.

severe North American blastomycosis

Histoplasmosis

Leishmaniasis, Visceral

Sporotrichosis

Mycoses

Cryptococcosis

Febrile Neutropenia

failed previous amphotericin B treatment

Used to treat failed previous amphotericin B treatment in combination with DL-dimyristoylphosphatidylcholine

severe Histoplasmosis

Visceral Leishmaniasis

severe Cryptococcosis

severe Systemic candidiasis

Mucocutaneous Leishmaniasis

Meningitis, Cryptococcal

Febrile Neutropenia

Leishmaniasis, Cutaneous

Gilchrist Disease

Coccidioidomycosis

Systemic candidiasis

Leishmaniasis, Mucocutaneous

Mycoses

Cerebral Cryptococcosis

HIV

Invasive Fungal Infections

Effectiveness

How Amphotericin B Affects Patients

Amphotericin B is a drug that is effective against many types of fungi, including Histoplasma capsulatum, Coccidioides immitis, Candida species, and more. It generally works well against Candida albicans but isn't as effective against other non-albicans species. Pseudallescheria boydii and Fusarium sp. are usually resistant to it. This drug does not work against bacteria, rickettsiae, or viruses.

How Amphotericin B works in the body

Amphotericin B is an antifungal drug that works by targeting and damaging the cell membrane of certain fungi. It binds to the sterols in the cell membrane, which disturbs the membrane and causes it to leak, leading to the death of the cell. Ergosterol, a type of sterol found in fungal cell membranes, is the primary target of amphotericin B.

When to interrupt dosage

The prescribed dosage of Amphotericin B is contingent upon the determined condition, such as Aspergillosis, serious Cryptococcosis and serious Mucocutaneous leishmaniasis. The amount of dosage can be found in the table below, based on the method of delivery.

Condition

Dosage

Administration

Cerebral Cryptococcosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Tuberculosis, Osteoarticular

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Aspergillosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Gilchrist Disease

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Coccidioidomycosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Systemic candidiasis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Mycoses

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Aspergillosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Cystitis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Histoplasmosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Leishmaniasis, Cutaneous

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Mycoses

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Sporotrichosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

failed previous amphotericin B treatment

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Leishmaniasis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Cryptococcosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Histoplasmosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Coccidioidomycosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Cryptococcosis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Endophthalmitis

, 5.0 mg/mL, 5.0 mg/mg, 1.0 mg/mg, 50.0 mg, 100.0 mg, 30.0 mg/mL, 10.0 mg/mL

Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Injection, lipid complex - Intravenous, Injection, lipid complex, Powder, for suspension - Intravenous, Powder, for suspension, Suspension - Intravenous, Suspension, Lotion - Topical, Cream - Topical, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Topical

Warnings

There are 20 known major drug interactions with Amphotericin B.

Common Amphotericin B Drug Interactions

Drug Name

Risk Level

Description

Cyclosporine

Major

Amphotericin B may increase the nephrotoxic activities of Cyclosporine.

Neomycin

Major

The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Neomycin.

Tenofovir

Major

Amphotericin B may increase the nephrotoxic activities of Tenofovir.

Tenofovir alafenamide

Major

Amphotericin B may increase the nephrotoxic activities of Tenofovir alafenamide.

Tenofovir disoproxil

Major

Amphotericin B may increase the nephrotoxic activities of Tenofovir disoproxil.

Amphotericin B Toxicity & Overdose Risk

The lowest toxic dose of Amphotericin B for rats has been found to be greater than 5gm/kg. An overdose of this drug can cause a sudden loss of heart and breathing function.

Amphotericin B Novel Uses: Which Conditions Have a Clinical Trial Featuring Amphotericin B?

10 active clinical trials are currently underway to evaluate the potential of Amphotericin B in managing Meningitis of Fungal Origin, Histoplasmosis and Fungal Infections.

Condition

Clinical Trials

Trial Phases

Tuberculosis, Osteoarticular

0 Actively Recruiting

Coccidioidomycosis

1 Actively Recruiting

Phase 2

Cerebral Cryptococcosis

1 Actively Recruiting

Phase 2, Phase 3

Mycoses

0 Actively Recruiting

Aspergillosis

0 Actively Recruiting

Cryptococcosis

0 Actively Recruiting

Histoplasmosis

0 Actively Recruiting

Meningitis, Fungal

0 Actively Recruiting

Histoplasmosis

1 Actively Recruiting

Phase 3

Systemic candidiasis

2 Actively Recruiting

Phase 2, Phase 3

Febrile Neutropenia

1 Actively Recruiting

Not Applicable

Cryptococcosis

0 Actively Recruiting

talaromycosis

0 Actively Recruiting

Leishmaniasis, Cutaneous

0 Actively Recruiting

Invasive Fungal Infections

2 Actively Recruiting

Phase 2, Phase 3

Endophthalmitis

0 Actively Recruiting

Mycoses

0 Actively Recruiting

Leishmaniasis, Mucocutaneous

0 Actively Recruiting

Aspergillosis

0 Actively Recruiting

Gilchrist Disease

0 Actively Recruiting

Patient Q&A Section about amphotericin b

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is amphotericin B mode of action?

"The way that Amphotericin B works is by binding to ergosterol in the fungal cell membrane. This creates pores that allow ions to escape, leading to the death of the fungal cell."

Answered by AI

What is amphotericin B used for?

"Amphotericin B injection is primarily used to treat serious and potentially life-threatening fungal infections. This medication works by slowing the growth of fungi that cause infection, making it an effective antifungal."

Answered by AI

Is amphotericin B an antibiotic or antifungal?

"Amphotericin B is an antibiotic that is considered the best option for treating life-threatening fungal infections. There are several proposed explanations for why it is so effective against fungi."

Answered by AI

What are the major adverse effects of amphotericin B?

"Fever and chills, headache, increased or decreased urination, irregular heartbeat, muscle cramps or pain, nausea, pain at the place of injection, unusual tiredness or weakness."

Answered by AI

Clinical Trials for Amphotericin B

Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Antibodies for HIV

18 - 55
All Sexes
Birmingham, AL

This study is testing a lab-made antibody called ePGT121v1-LS that targets a specific part of HIV. Researchers will give it by vein (IV) and under the skin (SC), both on its own and together with two other antibodies, VRC07-523LS and PGDM1400LS, which target different parts of the virus. They will assess safety and side effects, determine the right dose, study how the body processes the drug (pharmacokinetics or PK), and measure how well it neutralizes HIV in the blood (serum neutralizing activity). The expectation is that ePGT121v1-LS, whether given alone or with PGDM1400LS and VRC07-523LS, by IV or SC, will be safe in generally healthy adults and that the antibodies will not interfere with each other when used together. Approximately 83 volunteers in overall good health and without HIV-1 will be enrolled into two parts (A and B). Part A has six groups. In Groups 1-3, participants will get ePGT121v1-LS given by IV at one of three dose levels: 5 mg/kg, 20 mg/kg, or 40 mg/kg. In Groups 4-6, participants will receive three antibodies-first ePGT121v1-LS, then PGDM1400LS and VRC07-523LS-given by IV at two separate visits that are 24 weeks apart. The total study duration for participants in Part A is 48 weeks of scheduled clinic visits. Part B has two groups. In Group 7, people will get ePGT121v1-LS as SC shots at two visits 12 weeks apart. Each visit will give a total of 375 mg, split into three injections of 125 mg each. In Group 8, people will also have two visits 12 weeks apart and will receive three antibodies as SC shots in this order: first ePGT121v1-LS (125 mg), then PGDM1400LS (100 mg), and then VRC07-523LS (100 mg). The total study duration for participants in Part B is 24 weeks of scheduled clinic visits.

Phase 1
Waitlist Available

Alabama CRS (Site ID: 31788) (+5 Sites)

Image of Banner University Medical Center in Tucson, United States.

Olorofim for Valley Fever

18+
All Sexes
Tucson, AZ

This research study is being conducted to learn more about the use of olorofim in Coccidioidal (Cocci) meningitis, a rare but serious fungal infection that affects the brain and spinal cord. The study is exploratory, meaning that early information is being gathered to better understand the effectiveness of olorofim in coccidioidal meningitis in its early stages. The study plans to enroll approximately 10 to 12 participants who have been recently diagnosed-within the last 4 to 8 weeks-and who do not have a ventriculoperitoneal (VP) shunt, a medical device sometimes used to relieve pressure in the brain. Participants will be followed for approximately 6 months, during which health information will be collected to evaluate disease progression and response to treatment. Participants may have the opportunity to enroll in the olorofim Managed Access Program to continue treatment after completion of the study period.

Phase 2
Waitlist Available

Banner University Medical Center

Fariba Donovan, MD, PhD

F2G Biotech GmbH

Image of New Jersey Community Research Initiative in Newark, United States.

AI-DBT for Suicide Prevention in HIV/AIDS

18+
All Sexes
Newark, NJ

One in four older persons living with HIV/AIDS (PLWHA) report at least one suicide attempt in their lifetime, and the risk for death by suicide is 100 times higher in PLWHA than in the general population. Currently, there are no behavioral interventions that specifically address suicide prevention for older PLWHA, despite their unique biopsychosocial and structural risk factors. Through this work, investigators will adapt Dialectical Behavior Therapy, an evidence-based intervention for suicide prevention, for patients with PLWHA to be delivered by an AI-powered conversational Agent developed by our industry partner, Empower Health. Investigators will then pilot test the feasibility, usability, acceptability and preliminary efficacy to improve self-efficacy to manage negative emotions in n=50 older adults living with HIV/AIDS.

Recruiting
Has No Placebo

New Jersey Community Research Initiative (+1 Sites)

Elissa Kozlov, PhD

Have you considered Amphotericin B clinical trials?

We made a collection of clinical trials featuring Amphotericin B, we think they might fit your search criteria.
Go to Trials
Image of The University of Alabama at Birmingham in Birmingham, United States.

Behavioral vs Mindfulness Treatments for Insomnia in HIV

50 - 99
All Sexes
Birmingham, AL

The goal of this clinical trial is to examine the effects of a telephone-delivered Brief Behavioral Treatment Insomnia (BBTI) versus a Brief Mindfulness Treatment (BMT) on cognitive and sleep outcomes in older adults with HIV. The main questions it aims to answer are: What are the effects of BBTI vs BMT on self-reported and observed sleep outcomes in older adults with HIV and insomnia up to 1-year post-intervention? What are the effects of BBTI vs BMT on self-reported and observed cognitive comes in older adults with HIV and insomnia up to 1-year post-intervention? What is the association between Alzheimer's Disease biomarkers and sleep and cognitive outcomes in older adults with HIV receiving BBTI vs BMT? Participants will: * Complete 4 weeks of telephone-delivered BBTI or BMT * Attend baseline, post-intervention, and 1-year post in-person visits for sleep and cognitive assessments * Have blood collected at all three time points

Waitlist Available
Has No Placebo

The University of Alabama at Birmingham (+1 Sites)

Dr. Shameka L Cody, PhD, AGNP-C, PMHNP-BC, FAAN

Image of University of Minnesota in Minneapolis, United States.

LAmB and Posaconazole for Histoplasmosis

18+
All Sexes
Minneapolis, MN

The purpose of the study is threefold: 1. Assess the safety and efficacy of a single high-dose intravenous (LAmB 10mg/kg) compared to the SOC daily dosing (3mg/kg) of the same medication for induction therapy in moderate to severe histoplasmosis. 2. Assess the safety and efficacy of oral posaconazole 300mg delayed-release tablets three times daily for two days then once daily for consolidation therapy compared to SOC oral itraconazole 200 mg capsules three times daily for three days then twice daily in moderate to severe histoplasmosis 3. Assess the safety and efficacy of 6 months of consolidation therapy compared to the SOC 12 months of consolidation therapy in persons with HIV on appropriate antiretroviral therapy.

Phase 3
Waitlist Available

University of Minnesota

Nathan Bahr, MD

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL

The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.

Phase < 1
Waitlist Available

University of Alabama at Birmingham

Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA

This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.

Waitlist Available
Has No Placebo

Los Angeles General Medical Center

Hayoun Lee, PhD

Have you considered Amphotericin B clinical trials?

We made a collection of clinical trials featuring Amphotericin B, we think they might fit your search criteria.
Go to Trials
Image of Center on Substance Use and Health in San Francisco, United States.

CHAMPION Intervention for Pre-exposure Prophylaxis Adherence

18 - 40
Male
San Francisco, CA

The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are: * To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates. * To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.

Waitlist Available
Has No Placebo

Center on Substance Use and Health

Glenn-Milo Santos, PhD, MPH

Have you considered Amphotericin B clinical trials?

We made a collection of clinical trials featuring Amphotericin B, we think they might fit your search criteria.
Go to Trials